Mesenchymal Stem Cells Prevent the Rejection of Fully Allogenic Islet Grafts by the Immunosuppressive Activity of Matrix Metalloproteinase-2 and -9 by Ding, Yunchuan et al.
Mesenchymal Stem Cells Prevent the Rejection of Fully
Allogenic Islet Grafts by the Immunosuppressive Activity
of Matrix Metalloproteinase-2 and -9
Yunchuan Ding,
1 Danmei Xu,
2 Gang Feng,
1 Andrew Bushell,
1 Ruth J. Muschel,
2 and Kathryn J. Wood
1
OBJECTIVE—Mesenchymal stem cells (MSCs) are known to be
capable of suppressing immune responses, but the molecular
mechanisms involved and the therapeutic potential of MSCs
remain to be clariﬁed.
RESEARCH DESIGN AND METHODS—We investigated the
molecular mechanisms underlying the immunosuppressive ef-
fects of MSCs in vitro and in vivo.
RESULTS—Our results demonstrate that matrix metalloprotein-
ases (MMPs) secreted by MSCs, in particular MMP-2 and MMP-9,
play an important role in the suppressive activity of MSCs by
reducing surface expression of CD25 on responding T-cells.
Blocking the activity of MMP-2 and MMP-9 in vitro completely
abolished the suppression of T-cell proliferation by MSCs and
restored T-cell expression of CD25 as well as responsiveness to
interleukin-2. In vivo, administration of MSCs signiﬁcantly re-
duced delayed-type hypersensitivity responses to allogeneic an-
tigen and profoundly prolonged the survival of fully allogeneic
islet grafts in transplant recipients. Signiﬁcantly, these MSC-
mediated protective effects were completely reversed by in vivo
inhibition of MMP-2 and MMP-9.
CONCLUSIONS—We demonstrate that MSCs can prevent islet
allograft rejection leading to stable, long-term normoglycemia. In
addition, we provide a novel insight into the mechanism under-
lying the suppressive effects of MSCs on T-cell responses to
alloantigen. Diabetes 58:1797–1806, 2009
M
esenchymal stem cells (MSCs) were ﬁrst iso-
lated from bone marrow as stromal cells with
characteristics of clonal expansion and were
later identiﬁed as multipotent stem cells with
the capability to differentiate into various kinds of meso-
dermal tissues (1–3). Aside from their roles in contributing
to local microenvironments and supporting hematopoiesis
in bone marrow (4–6), MSCs can suppress T-cell prolifer-
ation in response to nominal antigens or alloantigens (7).
MSC-mediated inhibition is also associated with a reduc-
tion in inﬂammatory cytokine production (8).
Several soluble factors have been implicated in the
mechanism of MSC-mediated immunosuppression, includ-
ing transforming growth factor-, indoleamine 2,3-di-
oxygnase (IDO) (9), nitric oxide (NO) (10), and heme
oxygenase (HO)-1 (11). However, because of subtle differ-
ences in culture conditions, passage numbers, and the
input populations used in different studies, direct compar-
isons are difﬁcult and the mechanisms of MSC-mediated
suppression remain elusive. The precise role played by
speciﬁc molecules and whether this function is an exclu-
sive property of MSCs remain to be clariﬁed.
The use of MSCs for the treatment of graft versus host
disease (GvHD) after allogeneic bone marrow transplan-
tation has produced encouraging clinical results. Coinfu-
sion of MSCs with allogeneic hematopoietic stem cells can
accelerate hematopoietic recovery and prevent severe
GvHD refractory to conventional immunosuppressive
therapy (12,13). MSCs may also have signiﬁcant therapeu-
tic potential for the treatment of autoimmune disease,
such as experimental autoimmune encephalomyelitis (14),
collagen-induced arthritis (15), autoimmune enteropathy
(16), and experimental colitis (17), and in experimental
transplantation MSCs are capable of prolonging the sur-
vival of heart and skin allografts (18,19).
Islet transplantation offers an attractive and relatively
noninvasive therapy for patients with type 1 diabetes, but
although the Edmonton protocol and its derivatives have
shown great promise in terms of restoration of normogly-
cemia, they do not appear to provide long-term insulin
independence since most patients require exogenous in-
sulin within 2 years posttransplant (20,21). However, the
immunosuppressive effects of MSCs may have a particular
appeal as an adjunct therapy in islet transplantation be-
cause both clinical and experimental procedures lend
themselves to islet/MSC codelivery. In this study, we
demonstrate that MSCs can attenuate T-cell–mediated
rejection responses in a life-sustaining allogeneic islet
transplant model and shed new light on the mechanisms
involved.
RESEARCH DESIGN AND METHODS
Mice. CBA.Ca (CBA, H2
k), C57BL/6 (B6, H2
b), BALB/c (H2
d), and BALB/c
Rag
.
. mice were bred and housed in the Biomedical Services Unit of
John Radcliffe Hospital and were aged 6–8 weeks at the time of the ﬁrst
procedure.
MSCs. BALB/c (H2
d) bone marrow cells were ﬂushed from femurs and tibias
and cultured at 37°C with 5% CO2 in DMEM supplemented with 15% FCS, 2
mmol/l L-glutamine plus penicillin (6 g/ml) and streptomycin (100 units/ml),
and 0.5 mmol/l 2--mercaptoethanol. Primary MSCs were identiﬁed by mor-
phology, phenotypic analysis, and the capability to differentiate into adipo-
cytes and osteoblasts under appropriate culture conditions as described
previously (1,22).
Flow cytometry. Cell surface markers were stained using established tech-
niques. For analysis of intracellular plus surface CD25, cells were stained for
surface CD25 in the conventional manner then ﬁxed and permeabilized for 30
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DIABETES, VOL. 58, AUGUST 2009 1797min at 4°C (eBioscience) and incubated with CD25 antibody for intracellular
staining at 4°C for 30 min before acquisition.
Delayed-type hypersensitivity assay. For this assay, 7  10
6 C57BL/6
splenocytes as responders or 7  10
6 irradiated (20 Gy) CBA splenocytes as
stimulators were injected into the ear pinnae of immunodeﬁcient BALB/c
Rag
.
. mice either alone or together in the presence or absence of 1 10
5
MSCs using 30-gauge insulin syringes. Ear thickness was measured using a
spring-loaded micrometer before and 48 h after injection. Relative delayed-
type hypersensitivity (DTH) responses were calculated after 48 h, as previ-
ously described (23).
Islet isolation. Donor CB57L/B6 mice were killed by cervical dislocation.
Collagenase (0.25 mg/ml, Liberase RI; Roche Diagnostics) was infused via the
common bile duct. Pancreata were retrieved and digested for 10 min at 37°C
followed by vigorous agitation. Islet puriﬁcation was performed by Ficoll
gradient centrifugation at 1,230g for 22 min. Islets were visualized by dithizone
staining.
Adoptive transfer of cells and islet transplantation. BALB/c Rag
.
.
mice were reconstituted intravenously with 1  10
5 naïve BALB/c
CD4
CD25
 cells followed by transplantation of 500 B6 islets mixed with or
without 4  10
5 BALB/c MSCs beneath the kidney capsule. Blood glucose
levels were determined using a blood glucose meter (Roche Diagnostics).
Rejection was deﬁned as a blood glucose of 14.5 mmol/l for at least 2
consecutive days. In some experiments, graft dependence was determined by
removing the kidney containing the transplanted islets.
Visualization of transplanted islets. Kidneys were frozen in Tissue-Tek
OCT compound (Sakura) and 8-m sections stained with a guinea pig
anti-insulin antibody followed by a ﬂuorescein isothiocyanate (FITC)–conju-
gated anti–guinea pig second stage (both DakoCytomation). Nuclear counter-
staining was performed using Hoechst dye, and sections were viewed with a
Leica confocal microscope.
Statistics. Data, given as means  SE, were obtained from at least three
individual experiments, and statistical comparisons were performed using a
Student’s t test. Allograft survival between groups was compared using the
log-rank test (Graphpad Prism).
RESULTS
Primary BALB/c MSCs cultured from adherent bone mar-
row cells had a spindle morphology and exhibit a classical
MSC phenotype in that they are positive for CD44, CD73,
and CD106 but negative for CD11b (Fig. 1A) and positive
for Alizarin red and Oil Red O staining consistent with
osteogenic and adipogenic precursors, respectively (Fig.
1B and C).
MSCs induce interleukin-2 hyporesponsiveness in
T-cells. To examine the effect of MSCs on T-cell re-
sponses in vitro, T-cells were stimulated with anti-CD3/
CD28 beads with or without graded numbers of MSCs. As
shown in Fig. 1D, MSCs mediated suppression of T-cell
proliferation in a dose-dependent manner, resulting in a
83.5 and 34.3% inhibition at a ratio of 1:10 or 1:20 (MSC:
T-cell), respectively. More importantly, MSCs were capa-
ble of inhibiting T-cell responses driven by alloantigen. As
shown in Fig. 1E, the addition of MSCs at a ratio of 1:10
reduced the allogeneic T-cell response by 53.7% and at a
ratio of 1:1 abolished the proliferative response by 81.8%.
In a comparison with conventional CD4
CD25
 naturally
occurring Treg, preliminary experiments indicate that on a
cell-per-cell basis, MSCs appear to be approximately two
to four times more potent in terms of inhibition of in vitro
allogeneic T-cell responses (data not shown).
In many situations of in vitro T-cell hyporesponsiveness,
T-cell proliferation can be restored by the addition of
exogenous interleukin (IL)-2 (24,25). Therefore, we asked
whether the MSC-mediated suppressive activity on T-cell
proliferation could be rescued by the addition of IL-2.
Carboxyﬂuorescein succinimidyl ester (CFSE)-labeled T-
cells were stimulated in the presence or absence of MSCs
as in Fig. 1D and proliferation determined by CFSE
dilution. As shown in Fig. 2A, in the absence of MSCs,
virtually 90% of the T-cells proliferated, but this was
reduced to 	10% by the addition of MSCs. Surprisingly,
proliferation was not restored by the addition of exoge-
nous IL-2. We then evaluated whether stimulated T-cells
might regain their responsiveness to IL-2 after MSCs were
removed. Following stimulation with anti-CD3/CD28
beads in the presence or absence of MSCs, T-cells were
reisolated by positive selection then incubated with exog-
enous IL-2. As shown in Fig. 2B, while cells stimulated in the
primary culture without MSCs proliferated vigorously in
response to IL-2 in the secondary cultures, cells stimulated
initially in the presence of MSCs were unable to respond to
exogenous IL-2. Thus, MSC-mediated IL-2 unresponsiveness
appears to be a relatively stable phenomenon.
Activated T-cells lose surface expression of CD25 in
the presence of MSCs. In an attempt to explore this
phenomenon further, we examined the expression of three
surface markers that are upregulated as a consequence of
activation (CD69, CD44, and CD25). As shown in Fig. 2C,
while the presence of MSCs had no effect on the upregu-
lation of CD69 or CD44, the addition of MSCs resulted in a
signiﬁcant reduction in CD25 expression after 2 days. This
effect seemed to be speciﬁc to CD25 since the expression
of CD122 (IL-2R chain) and CD132 (IL-2R chain) were
unaffected by coculture (data not shown). Taken together,
these data suggest that the MSC-dependent inhibition of
both T-cell proliferation and responsiveness to IL-2 may be
due to a downregulation of CD25.
The reduced expression of CD25 on T-cells by MSCs
is not related to receptor internalization or tran-
scriptional regulation. Receptor internalization of sur-
face receptors into endocytic vesicles following ligand-
induced activation serves as an important mechanism in
the autonomous regulation to ligand stimulation and can
dramatically reduce receptor expression (26). To ask
whether this could explain the loss of surface CD25 on
T-cells in the presence of MSCs, T-cells were stimulated
with anti-CD3/CD28 beads and cocultured with MSCs
followed by extracellular staining or extracellular plus
intracellular staining for CD25. As a positive control for
the detection of intracellular CD25, activated T-cells were
incubated in the absence of MSCs with an excess of
unconjugated anti-CD25 antibody (PC61) to block surface
expression then stained with PC61-Pe with or without
permeabilization. This approach completely abolishes cell
surface staining (Fig. 3A, upper right panel), and thus the
staining shown in Fig. 3A, lower left panel is attributable
entirely to the detection of intracellular CD25. As shown in
Fig. 3B, while surface CD25 expression was upregulated in
the absence of MSCs, and reduced signiﬁcantly in the
presence of MSC, this was not explained by an increase in
intracellular CD25 since the surface and surface plus
intracellular proﬁles were essentially identical. Thus, re-
ceptor internalization does not appear to explain the
MSC-dependent reduction in CD25 expression.
We then asked whether the reduced expression of CD25
induced by coculture with MSCs was related to a reduc-
tion of CD25 transcripts during T-cell activation. Total
RNA was extracted and cDNA synthesized from either
resting T-cells or T-cells stimulated with anti-CD3/CD28
beads in the presence or absence of MSCs. The transcrip-
tional level of CD25 was determined by RT-PCR. Signiﬁ-
cantly, the reduction expression of CD25 induced by
coculture with MSCs was not reﬂected by changes at the
transcript level (Fig. 3C), suggesting that the effect of
MSCs on CD25 expression appears to be restricted to the
cell surface.
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1798 DIABETES, VOL. 58, AUGUST 2009MSC-mediated suppression is completely reversed by
blocking MMP-2 and MMP-9. It has previously been
suggested that the suppression of T-cell proliferation
mediated by MSCs is dependent on IDO (27), NO (10), and
HO-1 (11). To determine whether these molecules play a
role in the current system, speciﬁc inhibitors were added
to the cultures of T-cells stimulated in the presence of
graded numbers of MSCs. The inhibitors were used at
concentrations previously reported to compromise sup-
pression by MSCs. Inhibition of IDO (1-MT) and HO-1
(SnPP) had no effect individually on MSC-mediated T-cell
suppression (Fig. 4A). Addition of L-NG-monomethyl argi-
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FIG. 1. MSCs suppress T-cell proliferation in response to anti-CD3/CD28 cross linking or allogeneic antigen stimulation. A: MSCs obtained from
bone marrow cells of BALB/c (H2
d) mice show spindle-shaped morphology and exhibit a typical MSC phenotype (solid line), in which they are
positive for CD44, CD73, and CD106 but negative for CD11b. Isotype controls are represented as the shaded curve. B: MSCs were able to
differentiate into osteogenic and adipogenic lineages when subjected to inductive stimuli (B and C, induction) but not in control medium (B and
C, control). Osteogenic differentiation of MSCs was veriﬁed by Alizarin red staining (B). The presence of intracellular fat droplets detected by
Oil Red O staining indicates induced adipogenesis (C). D: CD4
CD25
 T-cells were puriﬁed from C57BL/6 (H2
b) mice using CD25 MicroBeads.
Standard 3-day cultures were set up in 96-well round-bottomed plates using 2  10
5 CFSE-labeled responder T-cells stimulated by CD3/CD28
Dynalbeads at a 1:1 bead:cell ratio in the presence of graded numbers of MSCs. CFSE division history was analyzed by ﬂow cytometry. The
percentage of proliferated cells was calculated by dividing the number of cells undergoing divisions with the total T-cells in the cultures. E: For
mixed leukocyte cultures, 2  10
5 CFSE-labeled CD4
CD25
 T-cells were cocultured with 5  10
5 irradiated (3,600 rad) CBA.Ca (H2
k)
splenocytes for 5 days. All the data above were obtained from three independent experiments. A high-quality digital representation of this ﬁgure
is available in the online issue.
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tially restored proliferation at an MSC:T-cell ratio of 1:10,
indicating that the MSC effect is at least partially depen-
dent on NO. Signiﬁcantly, however, the inhibition of
proliferation was completely reversed by addition of SB-
3CT, a speciﬁc inhibitor of MMP-2 and MMP-9, implicating
these enzymes as necessary and sufﬁcient for the inhibi-
tory activity of MSCs.
MMP-2 and MMP-9 are expressed and secreted into
the culture by MSCs. To determine whether the MSC
used in this study express MMP-2 or MMP-9, MSCs were
stained with speciﬁc antibodies and examined by ﬂuores-
cence microscopy. As shown in Fig. 4B, intracellular
MMP-2 and MMP-9 on MSCs were readily detected in MSC
cultures. To determine whether these enzymes were se-
creted as soluble forms, we collected the medium condi-
tioned by MSCs that had undergone 5 (P5) or 15 passages
(P15) and performed a Western blot for MMP-2 and
MMP-9. As shown in Fig. 4C, MSCs secrete both isoforms
as early as passage 5.
MMP-2 and MMP-9 from MSCs contribute to the loss
of expression of CD25 on T-cells. MMPs are zinc-
dependent enzymes that bind histidine-containing motifs
in components of the extracellular matrix and play a
crucial role in embryogenesis, wound healing, and tissue
remodeling (28–30). It has been determined that MMP-2
and MMP-9 may also play a role in immunological evasion
of cancer cells by clearing CD25 from T-cell surfaces (31).
The data in Figs. 4B and C conﬁrm that the MSCs used in
the present study contain and secrete MMP-2 and MMP-9,
and the data in Fig. 4A are consistent with a role for these
enzymes in MSC-dependent inhibition of T-cell responses
by cleavage of CD25 from the cell surface. To verify that in
our hands inhibition of MMP-2 and MMP-9 results in a
A B
C
FIG. 2. T-cell blasts cocultured with MSCs exhibited hyporesponsiveness to exogenous IL-2 and lost surface expression of CD25. A: CFSE-labeled
CD4
CD25
 T-cells from naïve C57BL/6 mice (H2
b) were cultured at a density of 2  10
5 per well in 96-well plates and stimulated with
anti-CD3/CD28 beads alone or in the presence of MSCs (2  10
4). Exogenous IL-2 was added at concentrations of 15, 50, and 100 IU/ml. After 72 h,
cell proliferation was analyzed by ﬂow cytometry. Data are represented as means  SD. Results are the average of three experiments of identical
design. B: Bars show the SD CD4
CD25
 T-cells were stimulated with anti-CD3/CD28 beads alone or in the presence of MSCs (MSC:T-cell ratio
of 1:10) for 72 h. CD4
 T-cells were puriﬁed by MACs anti-CD4 beads and cultured with 50 IU/ml IL-2 for 72 h. T-cell proliferation was measured
by 3H-Tdr incorporation added during the last8ho fculture. C: T-cells stimulated with anti-CD3/CD28 beads in the presence or absence of MSC
and harvested after 24 and 48 h. Surface expression of CD69, CD44, and CD25 was evaluated by ﬂow cytometry. Histograms are representative
of three independent experiments.
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1800 DIABETES, VOL. 58, AUGUST 2009detectable inhibition of MMP-dependent proteolysis, con-
ditioned medium from MSC cultures was separated by
SDS polyacrylamide electrophoresis in a gel containing
gelatin as an MMP substrate and analyzed by zymography
(32). The resultant gel was then incubated overnight at
37°C and the position-speciﬁc gelatin content determined
by densitometry. Addition of SB-3CT at a concentration of
6 mol/l resulted in a 52.4 and 90.5% inhibition of MMP-2
FIG. 3. Reduced expression of surface CD25 in the presence of MSCs is
not related to receptor internalization or reduced transcriptional
activity. A: As a positive control for intracellular CD25 detection,
activated T-cells were incubated with unconjugated PC61 then stained
with PC61-Pe with or without permeabilization or with an isotype
control. B: CD4
CD25
 T-cells from naïve C57BL/6 mice were stimu-
lated with anti-CD3/CD28 beads and cocultured with MSCs for 24, 48,
and 72 h followed by extracellular staining or extracellular plus
intracellular staining for CD25. The surface expression of CD25 (MFI)
was signiﬁcantly reduced at 48 and 72 h in the presence of MSCs, which
was not explained by an increase in intracellular CD25, since the
surface and surface plus intracellular proﬁles are essentially identical.
C: T-cells were stimulated with anti-CD3/CD28 beads in the presence
or absence of MSCs at the MSC:T-cell ratio of 1:10. Total mRNA was
extracted from bead-puriﬁed T-cells after coculture or from naïve
T-cells, and cDNA was synthesized using CMV reverse transcriptase.
For PCR, CD25 primers were as follows: CD25 forward primer 5-GAA
GCC AAC ACA GTC TAT GCA CC-3 and CD25 reverse primer 5-TGT
CCT TCC ACG AAA TGA TAG ATT C-3; and HPRT forward primer
5-ATC ATT ATG CCG AGG ATT TGG AA-3 and HPRT reverse primer
5-TTG AGC ACA CAG AGG GCC A-3.
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FIG. 4. MMP-2 and MMP-9 are involved in the immunosuppression by
MSCs. A: CFSE-labeled CD4
CD25
 T-cells stimulated with anti-CD3/
CD28 were cultured for 72 h in the presence or absence of MSCs. Cell
cultures were treated with 1 mmol/l 1-MT or 1 mmol/l L-NMM or 1
mmol/l SnPP or 6 mol/l SB-3CT. Proliferation was accessed by dilution
of CFSE ﬂuorescent intensity. Data from three independent experi-
ments each performed in triplicate are represented as means  SD. ,
control; E, 1-MT; Œ, L-NMMA; F, SnPP; *SB-3CT. B: MSCs were seeded
on 13-mm glass coverslips and ﬁxed, permeabilized, and blocked with
serum and incubated with mouse anti–MMP-9 or anti–MMP-2 monoclo-
nal antibodies. Binding was visualized using an Alexa Fluro 488
FITC-conjugated secondary, and cells were counterstained with
Hoechst 33342. Sections were examined using a Leica epiﬂuorescence
microscope. C: To collect conditioned medium, MSCs were washed with
PBS three times and resupplied with serum-free medium for 24 h. After
harvest, the MSC-conditioned medium was spun at 1,500g to remove
cellular debris, loaded on SDS-PAGE gels, and blotted with monoclonal
anti–MMP-2 or –MMP-9 antibodies. Recombinant mouse MMP-2 and
MMP-9 were used as markers. Data shown are representative of three
independent experiments. A high-quality digital representation of this
ﬁgure is available in the online issue.
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whether MMP-2 and/or MMP-9 can inﬂuence the surface
expression of CD25 (Fig. 2C), bead-stimulated T-cells
were cultured with MSCs in the presence or absence of
6 mol/l SB-3CT and CD25 expression evaluated by ﬂow
cytometry. As shown in Fig. 5B, the inhibitor partially
reversed the loss of CD25, and although the effect was
not complete, the fact that the same concentration of
inhibitor caused a complete abrogation of MSC depen-
dent T-cell inhibition (Fig. 4A) suggests that maximal
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FIG. 5. MSC-dependent reduction in CD25 expression by T-cells is
mediated by MMP-2 and MMP-9. A: Enzymatic activities of MMP-2
and MMP-9 in medium conditioned by MSCs were analyzed by
zymography. Conditioned medium was electrophoresed under non-
reducing conditions and without heating through a 8% SDS-PAGE
containing 0.1% gelatin. Following electrophoresis, the gels were
incubated overnight in developing buffer containing SB-3CT to
inhibit MMP activity. Gels were stained with Coomassie Blue, and
densitometric quantiﬁcation of MMP-2 and MMP-9 was performed
using Scion software. Data were obtained from three individual
experiments, and inhibition of MMP-2 and MMP-9 was determined
by setting the mock treatment as 100%. , control; f, SB-3CT. B:
To block activities of MMP-2 and MMP-9 in the MSC/T-cell cocul-
ture, SB-3CT was added at a concentration of 6 mol/l. Stimulated
T-cells alone (black curve) or cocultured with MSCs (dashed
curve) or MSCs treated with SB-3CT (gray curve) were examined
for surface expression of CD25. C: Stimulated T-cells were either
cultured alone (black curve) or in the presence of MSCs (MSC/T-
cell ratio of 1:10) (dashed curve). In some experiments, neutraliz-
ing monoclonal anti–MMP-2 or –MMP-9 antibodies were added
(gray shaded). Neutralizing antibody was used to block the activity
of MT1-MMP. IgG1 was used as an isotype control. T-cells were harvested at 72 h, stained with CD25-PE, and analyzed by ﬂow cytometry. D:
CD4
CD25
 T-cells were activated by 10 g/ml ConA for 24 h, washed three times to remove residual ConA, and resuspended in serum-free
medium at ﬁnal concentration of 2  10
5/ml. MMP-2 and MMP-9 recombinant proteins were added at ﬁnal concentration of 1 mg/ml. T-cells were
incubated with MMP recombinant proteins for an additional 6 h. MMP-2 or MMP-9 treated cells (solid curve) and untreated cells (dotted curve)
were analyzed for CD25 expression by ﬂow cytometry. Histograms of CD25 expression on T-cells are representative of three independent
experiments.
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responses to IL-2.
To determine whether both MMP isoforms contribute to
this effect, monoclonal antibodies speciﬁc for either
MMP-2 or MMP-9 were added to bead-stimulated T-cells
cultured with MSCs. As shown in Fig. 5C, while the CD25
median ﬂuorescence intensity (MFI) of T-cells cultured in
the absence of MSCs was 2,577  244, this fell to 281  55
in the presence of MSC. Signiﬁcantly, addition of anti–
MMP-2 resulted in a dose-dependent partial reversal of this
effect with 4 and 12 g/ml restoring CD25 expression to an
M F Io f6 0 5 45 and 1,252  102, respectively (Fig. 5C,
upper panel). A similar result was obtained by addition of
anti–MMP-9 antibody (Fig. 5C, middle panel). Importantly,
addition of an antibody to MT1-MMP, an isoform that has
previously been shown to be expressed by MSCs (33), had
no effect on CD25 expression. A direct effect of MMP-2 and
MMP-9 on CD25 expression is shown by the fact that
addition of puriﬁed recombinant proteins led to a modest
but detectable loss of CD25 expression by T-cells (Fig.
5D). Taken together, these data clearly implicate both
MMP-2 and MMP-9 in the MSC-mediated downregulation
of CD25 expression and the inhibition of T-cell responses.
Inhibition of MMP-2 and MMP-9 restores T-cell re-
sponses to IL-2. To determine whether inhibition of
MMP-2 and MMP-9 has a direct functional effect on T-cell
responses, CD4
 T-cells stimulated in primary culture in
the presence of MSCs were reisolated and recultured for
72 h in the presence of 5, 15, and 50 IU/ml exogenous IL-2.
As shown in Fig. 6, T-cells stimulated in the primary
culture without MSCs proliferated vigorously in response
to IL-2 in secondary culture, in clear contrast to the poor
proliferation of cells stimulated initially in the presence of
MSCs. However, inhibition of MSC MMP-2 and MMP-9 in
the primary culture resulted in essentially normal second-
ary responses to IL-2, providing a direct functional link
between the suppressive effect of MSC MMP activity and
CD25 expression, thereby suggesting that these enzymes
may contribute to the mechanism of MSC-mediated
immunosuppression.
MMP-2 and MMP-9 are critical in MSC-mediated sup-
pression in vivo. To test the hypothesis that MMPs play
a functional role in MSC-mediated suppression in vivo, we
used two models of T-cell responses to alloantigens. In the
ﬁrst, we used the trans vivo DTH assay, where ear swelling
provides a read-out of T-cell responses (34), and in the
second, we used life-sustaining allogeneic islet transplants
in diabetic mice (35). In the DTH assay, allogeneic stimu-
lator and responder cells were injected into the ear pinnae
of immune-deﬁcient mice in the presence or absence of
MSCs and with or without the MMP inhibitor SB-3CT. As
shown in Fig. 7A, coinjection of responders and stimula-
tors resulted in a threefold increase in ear swelling com-
pared with that induced by responders only. This DTH
response was virtually abolished by coinjection of MSC,
thus demonstrating a clear functional effect of these cells
in modulating allogeneic responses in vivo (***P 

0.001). Signiﬁcantly, however, administration of the SB-
3CT (6 mol/l) in the presence of MSCs reversed this
effect, resulting in virtually unmodiﬁed DTH responses
(***P 
 0.001).
One of the striking characteristics of MSC-mediated
suppression is the capability of these cells to prolong the
survival of skin allografts (18) and heart (19). However,
these grafts are physiologically passive and thus provide
only a limited indication of the potential of MSCs. As a
more rigorous test, we asked whether the immunosup-
pressive effects of MSCs would lead to the survival of
life-sustaining islet allografts in streptozotocin (STZ)-in-
duced diabetic recipients. C57BL/6 (H2
b) pancreatic islets
were transplanted under the kidney capsule of diabetic
BALB/c Rag
.
. mice, which were reconstituted intra-
venously with 1  10
5 CD4
CD25
 BALB/c T-cells as an
effector population. Blood glucose was monitored daily,
and diabetes was deﬁned by a level of 14.5 mmol/l on 2
successive days. Transplantation of 500 islets resulted in a
rapid return to normoglycemia (Fig. 7B), but mice trans-
planted with islets alone become profoundly diabetic
within 30–35 days (median survival time [MST] 
 30 days,
n 
 6) as a result of unmodiﬁed allograft rejection. In
striking contrast, administration of 1  10
5 syngeneic
MSCs mixed with the islets at the time of transplantation
prevented rejection, and all animals remained normogly-
cemic long term (n 
 6). That this was due solely to
survival of the transplanted islets and not to endogenous
islet regeneration is demonstrated by the fact that removal
of the transplanted islets by nephrectomy at day 95 (Fig.
7B, arrow) resulted in an abrupt return to hyperglycemia.
Signiﬁcantly, insulin-positive islets were readily detected
in these excised kidneys but were virtually absent from
mice transplanted without administration of MSCs (Fig.
7C).
To ask whether this protective effect is dependent on
the activity of MMP-2 and MMP-9, a third group of diabetic
recipients was transplanted with allogenic islets reconsti-
tuted with effector cells and MSCs, but these animals also
received the MMP-2 and MMP-9 inhibitor SB-3CT (25
g/mouse) intraperitoneally once every 4 days from the
day of islet transplant until rejection. All animals in this
group became profoundly diabetic within 30 days (MST 

30 days, n 
 4), again implicating MMP-2 and MMP-9 in
MSC-mediated immunosuppression in vivo (Fig. 7B).
DISCUSSION
Emerging evidence indicates that MSCs can suppress
T-cell responses both in vitro and in vivo, but the mecha-
nisms underlying these effects are not yet clearly deﬁned.
In this study, we have conﬁrmed the ability of MSCs to
FIG. 6. Inhibition of MMP-2 and -9 reverses MSC-induced T-cell
nonresponsiveness to IL-2. Anti-CD3/CD28–stimulated T-cells were
cultured alone or in the presence of untreated MSCs or MSCs treated
with SB-3CT. After 72 h, CD4
 T-cells were puriﬁed using MACs
anti-CD4 beads and incubated with IL-2 at concentrations of 5, 15, and
50 IU/ml. Proliferation was measured by 3H-Tdr incorporation. Data
from three independent experiments, each performed in triplicates,
are presented as means  SD. , MSC; f, MSC; Œ, MSC  SB-3CT.
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with MSCs results in impaired T-cells responses to IL-2.
The basis of this hyporesponsiveness appears to be due to
a preferential loss of CD25 (the -chain of the IL-2
receptor) from the cell surface, and, signiﬁcantly, this was
not explained either by receptor internalization or a reduc-
tion in CD25 expression at the transcriptional level. In an
examination of candidate molecules that have been impli-
cated in MSC-mediated suppression (9–11), we were in-
trigued by the observation that addition of the MMP-2– and
MMP-9–speciﬁc inhibitor, SB-3CT, reversed the suppres-
sion by MSCs. Whereas inhibition of IDO, HO-1, or NO led
to either no effect or only partially restored T-cell prolif-
eration, inhibition of MMP-2 and MMP-9 in the primary
coculture of T-cells with MSCs restored T-cell responses
to IL-2 in secondary MSC-free cultures, and this was
associated with restored levels of CD25 expression. Criti-
cally, the role of MMP-2 and MMP-9 in MSC-mediated
suppression in vivo was demonstrated by the DTH assay,
which provides an indirect read-out of T-cell responses.
More persuasively, however, the effect of MSC was also
demonstrated in a life-sustaining islet transplant model,
where sustained normogylcemia provides a direct and
physiologically relevant indication of attenuated T-cell
responses. Overall, the data suggest that one of the prin-
cipal explanations for the immunosuppressive capacity of
MSCs is the cleavage of CD25 from the T-cell surface by
MSC-secreted MMPs. Precisely where this takes place in
this model is not clear at present, but given the fact that
the MSCs are colocalized at the graft site, we would argue
that their major effect is mediated within the graft itself.
We predict, therefore, that the MSCs may have little effect
on T-cell sensitization in secondary lymphoid tissues but
rather that MMP-dependent cleavage of CD25 from the
T-cell surface is restricted to the peritransplant area and
thus limits prolonged T-cell activation. We are currently
testing this hypothesis by looking for differential levels of
CD25 on T-cells from the graft site and the draining lymph
nodes.
Besides their important role in modiﬁcation of the
extracellular matrix, cell–extracellular matrix interac-
tions, and cell mobilization, MMPs have been identiﬁed to
possess a broader range of substrate speciﬁcity that in-
cludes cytokines and other inﬂammatory mediators, with
consequent effects on regulation of the immune response
and cell proliferation (30,36). In the ﬁeld of cancer, MMP-2
and MMP-9 have been shown to play a direct role in
tumor-mediated immunosuppression by cleaving CD25
from the T-cell surface (31), and our study suggests that
while these enzymes that have a detrimental effect on
tumor immunity, they may explain the beneﬁcial effects of
MSCs on the control of GvHD and allograft rejection.
In view of their immunosuppressive effects on the
immune system, MSCs have signiﬁcant therapeutic poten-
tial for the treatment of immune-related diseases that are
refractory to conventional medical therapy. For example,
pilot clinical studies have shown that MSCs are effective in
the treatment of refractory acute GvHD, a severe compli-
cation that can occur following allogeneic bone marrow
transplantation (12). MSCs have also been shown to be
useful in the treatment of autoimmune diseases including
experimental autoimmune encephalomyelitis (14), collagen-
induced arthritis (15), and autoimmune enteropathy (16).
Despite the well-documented inhibitory activities of MSCs,
and the clinical trials investigating the therapeutic poten-
tial of these cells in the treatment of immune-mediated
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FIG. 7. Prevention of DTH responses and protection of allogeneic islet
grafts by MSCs is dependent on MMP-2 and MMP-9. A:7 10
6
responder cells (C57BL/6) or 7  10
6 irradiated stimulator cells
(CBA.Ca) were injected into the ear pinnae of BALB/c Rag
.
. mice
either alone or together in the presence or absence of 1 10
5 MSCs.
DTH response–induced ear swelling was calculated by subtracting the
thickness before injection from the thickness after 48 h. Administra-
tion of MSCs led to profound reduction of the alloreactive DTH
response, which was reversed in the presence of the inhibitor SB-3CT.
Data shown are means  SD of a representative of at least three
independent experiments. B: BALB/c Rag
.
. were rendered dia-
betic by a single intravenous injection of 200 mg/kg STZ. Mice had an
average blood glucose concentration of 20 mmol/l immediately prior
islet transplantation. A total of 500 IE pancreatic islets from CB57/B6
mice (H2
b) alone or in the presence of 4  10
5 BALB/c MSCs (H2
d)
were transplanted under the kidney capsules of STZ-induced diabetic
BALB/c Rag
.
.. In some experiments, MSCs were pretreated with
6 mol/l SB-3CT for 48 h and mice receiving treated MSCs also received
SB-3CT (25 g/mouse) intraperitoneally once every 4 days from the
day of islet transplant until rejection. All islet transplant recipients
were reconstituted with 1  10
5 naïve BALB/c CD4
CD25
 T-cells as an
effector T-cell population. Rejection was deﬁned as a blood glucose
>14.5 mmol/l for at least 2 consecutive days. Continued function of the
islet allografts was conﬁrmed by removal of the islet-bearing kidneys and
a return to hyperglycemia. C: Kidneys transplanted with islets grafts were
excised at the time of rejection or the end point of this study. Immuno-
ﬂuorescence examination of islet grafts in MSC-treated recipients re-
vealed intensely staining insulin producing islets beneath the kidney
capsule, whereas in the MSC-untreated recipients the insulin-positive
islet tissue was not detected at the time of rejection. A high-quality digital
representation of this ﬁgure is available in the online issue.
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solid organ transplantation, and, furthermore, the mecha-
nisms of MSC-mediated immunosuppressive effects in vivo
remained to be elucidated (37). Thus far, Bartholomew et
al. (18) have shown a single intravenous administration of
donor-type MSCs into major histocompatibility complex–
mismatched baboons prolonged the survival of skin grafts
to 11.8  1.4 days compared with 7.0  0 days in untreated
controls. In a mouse allograft model, Casiraghi et al. (19)
demonstrated that intraportal administration of MSCs
prolong heart allograft survival to a median survival time
of 40 days compared with 10 days in untreated controls.
The therapeutic potential of MSCs in islet transplan-
tation could address both aspects of these immune
responses by suppression of the alloreactivity and auto-
immunity (38,39). The current study shows that adminis-
tration of MSCs can result in the prolonged survival of
allogeneic islets and lead to long-term stable normoglyce-
mia. Moreover, inhibition of the activity of MMP-2 and
MMP-9 in vivo after cotransplantation of MSCs and allo-
geneic islet grafts abrogated the protective effect of the
MSCs, resulting in rejection of the transplanted islets.
Although our studies do not address the autoimmune
component of responses to transplanted islets, we would
argue on the basis of the relative precursor frequency of
direct-pathway alloreactive T-cells and self-restricted au-
toreactive T-cells that control of the rejection response
might also limit a reoccurrence of the original disease,
especially when MSC delivery was combined with tran-
sient immunosuppression to target self-restricted memory
T-cells. Taken together, our data demonstrate that MSCs
can inhibit the immune response to allogeneic tissue in
vivo and that MMP-2 and MMP-9 contribute to the molec-
ular mechanism of suppression mediated by MSCs in vitro
and in vivo and thus cement the rationale for their
therapeutic implication in allogeneic islet transplantation.
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